Press releases

December 11, 2013 Invitae Offers BRCA1/BRCA2 Testing, Providing Clinicians with a Reliable, Fast, Affordable Option for Patients
SAN ANTONIO, December 11, 2013 – Invitae Corporation, a genetic diagnostics company, today announced at the 2013 San Antonio Breast Cancer Symposium that it now offers BRCA1 and BRCA2 testing globally, providing clinicians with a reliable, fast and affordable option for their cancer patients.  Available with a turnaround time of just two weeks, this test includes full gene sequencing for both BRCA1 and BRCA2, as well as deletion/duplication analysis.  The test is globally available and is priced at $1,500 in the United States. Additionally, Invitae enables the ordering clinician to look beyond BRCA to understand additional risk factors for hereditary cancer by offering them the opportunity to upgrade to larger hereditary cancer panels at no additional cost and with the same two-week turnaround time.  The BRCA genes were the first to be associated with hereditary breast and ovarian cancer; however, there are several other genes that contribute to the risk of breast
Read more
December 10, 2013 Invitae Completes $40 Million Series E Financing
SAN FRANCISCO, December 10, 2013 -  Invitae Corporation, a genetic diagnostics company, today announced the completion of a $40 million Series E financing. Invitae will use the financing to accelerate the ongoing development of the company’s clinical genetic tests for hereditary disorders, including oncology, neurology and pediatric medicine. Invitae will also focus on expanding to international markets. Investors participating in the Series E round include Genomic Health, Inc. (NASDAQ: GHDX), Randy Scott, Thomas McNerney & Partners, Redmile Group, Genesys Capital, Casdin Capital, among others. “Invitae is making significant progress in expanding our genetic testing services and executing on our business plan.  With the support of our new and existing investors, this financing will allow us to expand our offering of genetic tests and build on our commercial capabilities,” said Randy Scott, PhD, founder and chief executive officer of Invitae. “This financing will help us
Read more
December 2, 2013 Invitae Files Suit Against Myriad Genetics
SAN FRANCISCO, December 2, 2013 – Invitae Corporation, a genetic diagnostics company, today announced that it filed an action in the U.S. District Court for the Northern District of California against Myriad Genetics, Inc. (NASDAQ: MYGN).  By its suit, Invitae seeks a declaration that certain Myriad patents relating to the BRCA1, BRCA2 and MUTYH genes are invalid and are not infringed by Invitae.  Invitae’s announcement today reinforces its commitment to defend its right to provide naturally occurring genetic information and services to physicians for their cancer patients (see Invitae Responds to Myriad Genetics Lawsuit). Earlier this year, the Supreme Court ruled that naturally occurring DNA and the information it encodes cannot be patented (Assn’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 [2013]) and thus ushered in a new era of personalized medicine.  Moreover, the Supreme Court’s June decision followed its prior ruling establishing that
Read more
November 26, 2013 Invitae Responds to Myriad Genetics Lawsuit
SAN FRANCISCO, November 26, 2013 – Invitae Corporation, a genetic diagnostics company, today announced that it plans to defend its right to provide naturally occurring genetic information and services to physicians for their cancer patients through its genetic testing services.  Invitae has been named a defendant in a lawsuit filed by Myriad Genetics, Inc. regarding Invitae’s BRCA and MUTYH genetic tests. Invitae disagrees with the allegations of the lawsuit and plans to vigorously defend itself against the lawsuit, which it believes has no merit.  Earlier this year, the Supreme Court ruled that naturally occurring DNA and the information it encodes cannot be patented (Assn’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 [2013]) and thus ushered in a new era of personalized medicine.  This followed on a prior Supreme Court ruling establishing that naturally occurring biological correlations were not patentable subject matter (Mayo Collaborative
Read more
September 20, 2013 Invitae Chile, presenting the "Future of Genetic Medicine" in Santiago
En Español: Santiago, Chile – September 20, 2013 - Invitae Corporation, headquartered in San Francisco, California, has announced that Genometrics, a Chilean company located in Santiago, will be the exclusive partner for the Invitae Chile SpA in Chile.  Invitae is a genetic diagnostics company specializing in genetic testing for hereditary diseases in oncology, cardiology, neurology and pediatric medicine.  Invitae previously announced that it will have a fully operational laboratory for the purpose of providing these tests for the Latin American medical community. The goal of the partnership is to bring the science of genetic medicine to the clinic through an experienced local partner who can facilitate access and education for clinicians to the Invitae offering “The Chilean medical community will now have access to genetic testing to enable patients and physicians to obtain
Read more
September 7, 2013 Invitae Announces Results of Hereditary Breast Cancer Study in Collaboration with Stanford University
Presentation at ASCO Breast Symposium demonstrates that next-generation DNA sequencing technology accurately identifies BRCA 1 and 2 mutations and multi-gene testing adds value beyond BRCA 1 and 2 for cancer patients. San Francisco, CA, September 07, 2013. Invitae, Inc., a genetic information company, today announced the results of a study conducted in collaboration with Stanford University assessing hereditary breast and ovarian cancer risk using a multi-gene next-generation sequencing panel. The results showed that analysis of BRCA1/2 mutations produced results concordant with prior clinical testing and also identified additional pathogenic variants in genes other than BRCA1/2. The study was presented by Allison Kurian, M.D., assistant professor of Medicine (Oncology) and Health, Research and Prevention and the associate director of the Breast Cancer Genetics Clinic at Stanford, during the Poster Discussion Session A at the American Society of Clinical Oncology (ASCO) Breast
Read more
June 13, 2013 International Initiative Applauds the Supreme Court Decision Eliminating Gene Patents and Announces the Launch of a Public Database for Hereditary Gene Mutations
San Francisco, California -  A consortium of policy makers, advocacy organizations, individuals, academic centers and industry today announced the formation of a first-of-its kind initiative,  Free the Data!,  to fill the public information gap caused by the lack of available genetic information for the BRCA1 and BRCA2 genes and plans to expand to provide other types of genetic information in open, searchable databases, including the National Center for Biotechnology Information’s database, ClinVar.  The primary founders of this project include Genetic Alliance, University of California San Francisco (UCSF), Invitae Corporation and patient advocates. Women with certain variations in the BRCA 1 and BRCA2 genes can have significant increases in their lifetime risk for breast and ovarian cancer. Faced with these odds, women who are diagnosed with a BRCA mutation often have to make difficult decisions.  Free the Data! empowers women to impact health
Read more
June 12, 2013 Llega a Chile Test Genético que Detecta 264 Enfermedades - La Tercera
Read more
May 30, 2013 Invitae Establishes an International Subsidiary and State-of-the-Art Genetic Testing Facility in Chile, Partnership with Biotech Pioneer, Pablo Valenzuela
En Español: Santiago, Chile - Invitae Corporation announced today the establishment of a South American subsidiary, Invitae Chile SpA, and a partnership with biotechnology pioneer, Pablo Valenzuela and the Fundación Ciencia & Vida, to establish a production facility in Santiago, Chile. Dr. Valenzuela is a well-known biotechnology entrepreneur who co-founded Chiron in 1981 and the Fundacion in 1997. The new entity is being formed to service global markets with genetic information that will inform routine medical practice and influence everyday health decisions. The Chilean facility will be a state of the art, next generation DNA sequencing facility that is a mirror image of Invitae’s CLIA laboratory in San Francisco, California.  Both the U.S. and Chilean laboratories will have the capability to process tens of thousands of samples per year and can be scaled as the market grows. As
Read more


The information in the press releases, presentations, webcasts and publications is archival and should be considered accurate only as of its date. We disclaim any obligation to supplement or update the information in these documents, presentations or webcasts.


This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including those risks and uncertainties detailed from time to time in Invitae Corporation’s periodic filings with the Securities and Exchange Commission. Invitae Corporation specifically disclaims any obligation to update any forward-looking statements.

Forward Looking Statements

Investor Toolkit

Feature Presentation

Email Alerts

Sign up to receive Invitae financial information by email.
Email Address: *

Enter the code shown above.

Investor Contact

1400 16th St.
San Francisco, CA, 94103